Adults 18 to 100, any sex, with Cancer or Thoracic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Participants With Change in Their Physician-assessed Burden ScorePrimary· Up to 2 months
The primary outcome is patients with any change in physicians-assessed burden scores for at least one radiotherapy on-treatment visit. Lee et al. demonstrated the feasibility of using a global burden score to capture the provider's overall perception of the combined burden of all assessed symptoms, using a visual analogue scale demarcating an aggregate score from 0 to 10. This scale uses anchors at 0, 2, 4, 6, 8, and 10 for no, mild, moderate, severe, life-threatening adverse events, and death, respectively. A 2-point score change correlates to a change to the next anchored score (i.e., mild t
Patients with an increased or decreased burden-score of 1 point.
Group
Value
95% CI
Patients With Cancer Treated With Definitive-intent Radiotherapy
43
Patients with an increased or decreased burden-score of ≥ 2 points.
Group
Value
95% CI
Patients With Cancer Treated With Definitive-intent Radiotherapy
32
Patients with no change in burden-score.
Group
Value
95% CI
Patients With Cancer Treated With Definitive-intent Radiotherapy
25
Participants With Changes in the Management of On-treatment SymptomsSecondary· Up to 2 months
During weekly on-treatment visits and prior to reviewing the patient's PROMs, physicians will formulate an initial symptom management plan based on available clinical data. After reviewing the patient's PROMs, physicians will report participants with changes in recommended interventions due to review of the PROMs.
New Medications/ New Interventions
Group
Value
95% CI
Patients With Cancer Treated With Definitive-intent Radiotherapy
29
Counseling/ Modification of Medications
Group
Value
95% CI
Patients With Cancer Treated With Definitive-intent Radiotherapy
39
Referral to Other Services/ Further Tests
Group
Value
95% CI
Patients With Cancer Treated With Definitive-intent Radiotherapy
19
Sponsor's own description
Patient-reported outcome measures (PROMs) is an umbrella term that refers to any report on a health status measure that is reported directly by the patient, without the influence of clinicians or anyone else. PROMs have been shown to more closely reflect a patient's daily health status when compared to physician-reported measures. However, research is needed to evaluate if patient symptom reporting during definitive-intent radiotherapy allows earlier and improved detection of treatment toxicity.
The IMPROVE pilot study will describe the proportion of patients with cancer with changes in physician-perception of treatment-related toxicity that result from routine physician review of PROMs reported during definitive radiotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors
· NA
· recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy
· NA
· recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients.
· NA
· recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations
· NA
· recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
· NA
· recruiting
Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials
Trials by the same sponsor.
NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
· Phase 1
· not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+
· Phase 2
· not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors
· NA
· not yet recruiting
NCT07140315 — DK222 Study at Hopkins
· Phase 1
· recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove
· EARLY_PHASE1
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04589247.